There are 2789 resources available
504P - Prognostic factors of patients with AFP-positive colorectal cancer: A case-control study
Presenter: Min-Yi Lv
Session: ePoster Display
505TiP - REGINA: A phase II trial of neoadjuvant regorafenib (rego) in combination with nivolumab (nivo) and short-course radiotherapy (SCRT) in intermediate-risk, stage II-III rectal cancer (RC)
Presenter: Giacomo Bregni
Session: ePoster Display
506TiP - Pembrolizumab plus lenvatinib versus standard of care for previously treated metastatic colorectal cancer (mCRC): Phase III LEAP-017 study
Presenter: Takayuki Yoshino
Session: ePoster Display
507TiP - PRESERVE 1: A phase III, randomized, double-blind trial of trilaciclib versus placebo in patients receiving FOLFOXIRI/bevacizumab for metastatic colorectal cancer
Presenter: Joleen Hubbard
Session: ePoster Display
509TiP - REPROGRAM-01, a phase II study of regorafenib in combination with a multimodal metronomic chemotherapy in patients with metastatic colorectal cancer
Presenter: Elodie Klajer
Session: ePoster Display
511TiP - A phase III, multicenter, open-label, randomized study to assess the efficacy and safety of cetuximab plus capecitabine versus cetuximab as maintenance treatment following first-line induction treatment with FOLFOX and cetuximab in Chinese patients with RAS and BRAF WT mCRC
Presenter: Dongsheng Zhang
Session: ePoster Display
521P - Dose escalation study of two different alternative dosing schedules of tusamitamab ravtansine (tusa, SAR408701) in patients (pts) with advanced solid tumors
Presenter: Maria Vieito
Session: ePoster Display
522P - Risk mitigation of ocular toxicities due to antibody drug conjugates (ADCs) in novel early-phase clinical trials
Presenter: Khobe Chandran
Session: ePoster Display